12/5
04:18 pm
wve
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove [Seeking Alpha]
Neutral
Report
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove [Seeking Alpha]
11/17
10:09 am
wve
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]
Low
Report
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead [Seeking Alpha]
11/16
10:26 pm
wve
Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]
Neutral
Report
Jefferies Maintains “Buy” Rating on Wave Life Sciences (WVE) Amid Its Improving Competitive Positioning [Yahoo! Finance]
11/13
06:30 am
wve
WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]
Medium
Report
WAVE Life Sciences Ltd (WVE) Q3 2025 Earnings Call Highlights: Promising Clinical Advances and ... [Yahoo! Finance]
11/11
10:10 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Wedbush from $18.00 to $20.00. They now have an "outperform" rating on the stock.
11/11
09:44 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an "overweight" rating on the stock.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $16.00. They now have an "overweight" rating on the stock.
11/10
07:59 am
wve
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/10
07:30 am
wve
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
High
Report
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
11/7
08:30 am
wve
Wave Life Sciences to Present at Upcoming Investor Conferences
Low
Report
Wave Life Sciences to Present at Upcoming Investor Conferences
11/4
08:30 pm
wve
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
Low
Report
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
11/4
08:30 am
wve
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
Low
Report
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
11/1
03:09 am
wve
Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript [Seeking Alpha]
Medium
Report
Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript [Seeking Alpha]
10/29
10:50 pm
wve
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Neutral
Report
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
10/29
04:15 pm
wve
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Low
Report
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
10/27
10:07 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
10/20
08:14 am
wve
WAVE Life Sciences (NASDAQ:WVE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $18.00 price target on the stock.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $18.00 price target on the stock.
10/10
08:11 pm
wve
Wave Life Sciences (WVE): A Valuation Deep Dive Following Pipeline Progress and Investor Optimism [Yahoo! Finance]
Low
Report
Wave Life Sciences (WVE): A Valuation Deep Dive Following Pipeline Progress and Investor Optimism [Yahoo! Finance]
9/24
04:09 pm
wve
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors [Yahoo! Finance]
Low
Report
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors [Yahoo! Finance]
9/18
08:55 am
wve
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences [Yahoo! Finance]
9/18
08:30 am
wve
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
Low
Report
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
9/10
08:05 pm
wve
Wave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 Study [Yahoo! Finance]
Low
Report
Wave Life Sciences (WVE) Sees Promising Results From RestorAATion-2 Study [Yahoo! Finance]
9/8
08:45 am
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $26.00 price target on by analysts at Leerink Partners.
High
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $26.00 price target on by analysts at Leerink Partners.
9/8
04:05 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at B. Riley.
High
Report
WAVE Life Sciences (NASDAQ:WVE) had its "buy" rating reaffirmed by analysts at B. Riley.